H
HLTguest
Guest
"GI197111X is a new dual 5-alpha reductase inhibitor which could be GlaxoSmithKline's successor to Dutasteride / Avodart. Because Glaxo already has a potent dual 5-alpha reductase inhibitor on the market (Avodart), there is no reason to conduct Phase I or II FDA clinical trials unless they believe it is superior to their existing marketed medicine for some reason."
http://www.regrowth.com/hairloss-remedy ... 97111x.cfm
http://www.regrowth.com/hairloss-remedy ... 97111x.cfm